Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MBFUN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
hz49E10H1H5L7-MMAE
|
|||||
| Synonyms |
hz49E10H1H5L7-MMAE
Click to Show/Hide
|
|||||
| Organization |
CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
hz49E10H1H5L7
|
Antibody Info | ||||
| Antigen Name |
Neural cell adhesion molecule L1 (L1CAM)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
| Special Approval(s) |
Investigative
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.092 nM | High L1CAM expression (L1CAM +++) | ||
| Method Description |
HeLa cells are cultured in DMEM complete medium (Corning, 10-013-CVR) containing 10% FBS (Gibco, 10099-141) and 100 U/mL penicillin-streptomycin mixture (Thermofisher, 15140122). When the cell coverage in the culture container reaches 80-90%, TrypLE (Thermofisher, 12604-013) is used to digest the HeLa cells from the culture container, and they are seeded in a 96-well cell culture plate (Greiner, 655098) at a density of 3.3X103 cells/mL, with 500 cells per well (145uL complete medium),and the 96-well plate is incubated at 37°C overnight. The next day, (ADC) is diluted in complete medium in a 4-fold serial dilution, with 9 concentration gradient points. Then, 5uL of dilution of the ADC molecule is added to each well in the 96-well cell culture plate, gently mixed, and the 96-well plate is incubated at 37°C for 6 days. Finally, 75 uL of CTG is added to each well, gently mixed, and the 96-well plate is incubated at room temperature for 10 minutes. Then the luminescence signal is detected using a multimode microplate reader (PerkinElmer Envision 2105). A dose-inhibition curve is generated, and the half-maximal inhibitory concentration (IC50) is calculated using non-linear regression with GraphPad software.
Click to Show/Hide
|
||||
| In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 90 nM | Low L1CAM expression (L1CAM+) | ||
| Method Description |
HeLa L1CAM-KO cells are cultured in DMEM complete medium (Corning, 10-013-CVR) containing 10% FBS (Gibco, 10099-141) and 100 U/mL penicillin-streptomycin mixture (Thermofisher, 15140122). When the cell coverage in the culture container reaches 80-90%, TrypLE (Thermofisher, 12604-013) is used to digest the HeLa L1CAM-KO cells from the culture container, and they are seeded in a 96-well cell culture plate (Greiner, 655098) at a density of 3.3X103 cells/mL, with 500 cells per well (145uL complete medium),and the 96-well plate is incubated at 37°C overnight. The next day, (ADC) is diluted in complete medium in a 4-fold serial dilution, with 9 concentration gradient points. Then, 5uL of dilution of the ADC molecule is added to each well in the 96-well cell culture plate, gently mixed, and the 96-well plate is incubated at 37°C for 6 days. Finally, 75 uL of CTG is added to each well, gently mixed, and the 96-well plate is incubated at room temperature for 10 minutes. Then the luminescence signal is detected using a multimode microplate reader (PerkinElmer Envision 2105). A dose-inhibition curve is generated, and the half-maximal inhibitory concentration (IC50) is calculated using non-linear regression with GraphPad software.
Click to Show/Hide
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | HeLa cells (L1CAM KO) | CVCL_0030 | ||